Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences | ||||
By: Nasdaq / GlobeNewswire - 10 Dec 2018 | Back to overview list |
|||
Data presented at the Annual World Congress of Digestive Disease in Rome, Nov. 30 - Dec. 2, and at the Antigen-Specific Immune Tolerance Europe Summit in London, Dec. 10 - 12
NANTES, France, Dec. 10, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) was invited to present data on OSE-127, its anti-interleukin-7 receptor (IL-7R) antibody, including preclinical results from inflammatory and autoimmune chronic disease models and ex-vivo human biopsies, at the Annual World Congress of Digestive Disease in Rome, Nov. 30 - Dec. 2, and at the Antigen-Specific Immune Tolerance Europe Summit in London, Dec. 10 - 12. The data presented, partially described in OSE’s recent publication in Nature Communications(1), highlight the differentiated mechanism of action of OSE-127, currently in a first-in-human Phase 1 study, and confirm the potential therapeutic value of its further clinical development in inflammatory bowel diseases:
“OSE-127 is highly differentiated by its mechanism of action, which makes it a true antagonist of IL-7R and more likely to deliver therapeutic benefits and we look forward to initiating Phase 1 clinical trial,” said Alexis Peyroles, CEO of OSE Immunotherapeutics. On Nov. 26, 2018, OSE Immunotherapeutics received authorization from the Belgian health authorities to initiate a Phase 1 clinical trial of OSE-127. This first-in-human dose-escalation, randomized, double-blind, placebo-controlled Phase 1 trial aims to evaluate the safety and tolerability of single- and multiple-ascending intravenous and subcutaneous doses of OSE-127 in 63 healthy volunteers. OSE-127 is being developed under an option license agreement with Servier* up to the completion of a Phase 2 clinical trial, planned in ulcerative colitis, a bowel autoimmune disease, and in parallel in Sjögren’s syndrome. *Servier is an independent international pharmaceutical company governed by a foundation with Headquarters based in France. ABOUT OSE-127 OSE Immunotherapeutics has signed a license option agreement with Servier in December 2016 for the development and commercialization of OSE-127. (2) Powell, N. et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity 37, 674–684 (2012) ABOUT OSE Immunotherapeutics Click and follow us on Twitter and Linkedln Contacts
Forward-looking statements These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
|
||||
|
||||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |